Bradford Hill criteria

Conclusions: Converging mechanistic, neuropathological, epidemiological, and genetic
evidence demonstrates that aluminum adjuvants can trigger ASD in genetically susceptible
individuals through well-characterized neuroinflammatory pathways. The 80-fold increase
in ASD prevalence temporally correlating with vaccine schedule expansion, combined with
robust biological mechanisms and postmortem findings, demands urgent re-examination of aluminum adjuvant safety in the context of neurodevelopment, particularly in genetically vulnerable populations.